Summary

Oligonucleotide Synthesis Market (3rd Edition): Industry Trends and Global Forecasts, Till 2035 - Application Area (Research and Diagnostics, and Therapeutics), Type of Product Synthesized (Active Pharmaceutical Ingredients and Finished Dosage Forms), Type of Oligonucleotide Synthesized (Antisense, DNA, siRNA and Other Oligonucleotides), Scale of Operation (Clinical and Commercial), Therapeutic Area (Cardiovascular Disorders, Genetic Disorders, Liver Disorders, Rare Diseases, and Other Disorders), End-Users (Pharmaceutical / Biopharmaceutical Companies, Academic and Research Institutes, and Hospitals), Company Size (Small, Mid-sized, and Large and Very Large) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World)
Report Link: https://www.rootsanalysis.com/reports/oligonucleotide-synthesis/304.html
The Oligonucleotide Synthesis Market is expected to reach USD 4.8 billion anticipated to grow at a CAGR of 9.9% during the forecast period 2024-2035.

Oligonucleotides, commonly known as oligos, are short segments of DNA or RNA molecules typically containing 10-50 nucleotides. Each oligonucleotide chain comprises a phosphate group, a sugar molecule (deoxyribose in DNA and ribose in RNA), and a nitrogenous base. DNA includes adenine (A), cytosine (C), guanine (G), and thymine (T), while RNA contains adenine (A), cytosine (C), guanine (G), and uracil (U). These molecules play crucial roles in genetic testing, molecular analysis, and various analytical procedures like artificial gene synthesis and polymerase chain reactions (PCR). The approval of Vitravene, the first antisense oligonucleotide drug, has broadened the applications of oligonucleotides beyond therapeutics to research and diagnostics. Numerous preclinical and clinical studies have underscored the potential of oligonucleotides as safe and effective treatment options, attributed to their high target specificity and superior pharmacokinetic profiles.

Globally, over 15 oligonucleotide-based therapies have gained approval, including recent examples like Amvuttra (2022), AMONDYS 45 (2021), Leqvio (2021), and Oxlumo (2020). Additionally, nearly 300 clinical studies are investigating approximately 80 oligonucleotides across 14 therapeutic areas for over 102 different indications, targeting 66 different genes. Chemical synthesis methods like phosphoramidite synthesis and solid-phase synthesis are predominantly used for oligonucleotide manufacturing. However, these methods face challenges such as prolonged development timelines, purification issues, and regulatory compliance concerns. Consequently, many researchers and developers in the oligonucleotide synthesis market opt to outsource manufacturing to contract service providers with the necessary expertise and capabilities. The global demand for oligonucleotides has surged, especially post the COVID-19 pandemic, owing to their widespread use in COVID-19 testing kits. As a result, contract service providers are expanding their capacities and capabilities to meet this increased demand. Furthermore, the growing pipeline of oligonucleotide-based drugs, promising clinical trial outcomes, and extensive research activities in the field are expected to create lucrative growth opportunities for custom/contract service providers in the foreseeable future.


Research Coverage:
This chapter offers a comprehensive overview of oligonucleotides and their various types. It explores the intricacies of custom oligonucleotide synthesis, detailing the steps involved in the process. Additionally, it delves into the chemical modification and purification techniques employed in oligonucleotide manufacturing. Moreover, the chapter sheds light on the challenges inherent in oligonucleotide manufacturing, such as regulatory constraints and technical intricacies. These hurdles have prompted a notable trend towards outsourcing manufacturing operations to specialized service providers. Furthermore, the chapter examines the key growth drivers and barriers in oligonucleotide manufacturing, along with upcoming trends in the field. Through this discussion, readers gain a thorough understanding of the oligonucleotide manufacturing landscape and its evolving dynamics.
This chapter conducts a comprehensive assessment of oligonucleotide synthesis providers, considering critical parameters like establishment year, company size, headquarters and synthesis facility locations, and operational scale. It evaluates the synthesis of various oligonucleotide types, including antisense, aptamers, DNA/RNA probes, primers, and others. Assessment extends to product types, including APIs and drug formulations, across research, diagnostic, and therapeutic applications. Additional services, such as method validation, testing, custom synthesis, and regulatory support, are also examined. Through this thorough evaluation, readers gain insights into the capabilities and offerings of oligonucleotide synthesis providers, facilitating informed decision-making in selecting industry partners.
This chapter conducts an extensive competitiveness analysis of oligonucleotide synthesis providers, focusing on key parameters like supplier and service strength. Supplier strength is evaluated based on industry experience, while service strength considers operational scale, types of oligonucleotides synthesized, application areas, product types, and additional services offered. The number of synthesis facilities operated by each provider is also a crucial factor in assessing competitiveness. Through this detailed analysis, readers gain insights into the competitive landscape of oligonucleotide synthesis providers, facilitating informed decision-making in selecting industry partners or suppliers.
Elaborate company profiles of prominent players (shortlisted based on our proprietary criteria) engaged in offering oligonucleotide synthesis services. Each profile features a brief overview of the company (including information on year of establishment, location of headquarters, number of employees and leadership team), financial information (if available), service portfolio, recent developments and an informed future outlook.
This section introduces an insightful make-versus-buy framework, exploring the factors influencing developers' decisions to outsource oligonucleotide manufacturing or establish in-house capabilities. It analyzes critical factors including cost, technological expertise, regulatory compliance, scalability, timelines, and strategic alignment. By considering these factors, sponsors and developers can make informed decisions aligned with their organizational goals, resources, and long-term strategies.
Elaborate analysis of completed, ongoing, and planned clinical studies evaluating various oligonucleotide therapeutics, based on several relevant parameters, such as trial registration year, trial status, trial phase, enrolled patient population, type of sponsor, most active industry players (in terms of number of trials conducted), study design, therapeutic area and key geographical regions.
Detailed assessment of the partnerships inked between stakeholders in this industry, since 2014, based on several parameters, such as year of partnership, type of partnership, type of oligonucleotide, therapeutic area, application area and the most active players (in terms of the number of partnerships signed). It also provides for the regional distribution of the companies involved in these agreements.
Elaborate assessment of expansion initiatives undertaken by oligonucleotide synthesis providers, during the period, since 2015, along with information on several relevant parameters, such as year of expansion, type of expansion, scale of operation, application area, amount invested, area of facility and location of expanded facility.
Insightful review of the various oligonucleotide-focused manufacturing initiatives undertaken by top 13 big pharma players (shortlisted on the basis of 2022 revenues), highlighting trends across various parameters, such as number of initiatives, year of initiative, type of initiative, type of initiative, scale of operation, type of oligonucleotide manufactured, and amount invested.
Comprehensive insight on the overall installed capacity for manufacturing of oligonucleotides, based on information reported by various industry stakeholders in the public domain. The analysis highlights the distribution of the available capacity based on the company size (small, mid-sized, and large and very large firms) and key geographical regions (North America, Europe and, Asia-Pacific and Rest of the World).

This chapter offers an informed estimation of the annual clinical demand for oligonucleotide therapeutics, considering the target patient population in ongoing and planned clinical trials sponsored by both industry and non-industry entities. Additionally, we estimate the commercial demand for oligonucleotides by analyzing the top 12 oligonucleotide-based therapies and phase III drugs. This estimation factors in parameters such as target patient population, dosing frequency, and dose strength. Through this analysis, readers gain insights into the anticipated clinical and commercial demand for oligonucleotide therapeutics, aiding strategic planning and decision-making in the industry.
Detailed assessment of the factors that can impact the growth of oligonucleotide synthesis services market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.
This section offers a detailed forecast of the oligonucleotide synthesis market, aiming to estimate both the present market size and future opportunities for the next 11 years. Utilizing various parameters and anticipated adoption trends, we have provided an informed estimate of the market size from 2024 to 2035. These estimations undergo validation through primary research and analysis to ensure accuracy and reliability. Through this forecast, readers gain insights into the projected growth trajectory and potential opportunities within the oligonucleotide synthesis market, facilitating strategic planning and decision-making for industry stakeholders.
Detailed projections of the current and future opportunity within the oligo synthesis market across different application area, such as research and diagnostics, and therapeutics.
Comprehensive projections of the current and future opportunity within the oligo synthesis market across different type of product synthesized, such as active pharmaceutical ingredients and finished dosage forms.
Elaborate projections of the current and future oligo synthesis market across different type of oligonucleotide synthesized, such as antisense, DNA, siRNA and other oligonucleotides.
Detailed projections of the current and future opportunity within the oligonucleotide synthesis market across different scales of operation, such as clinical and commercial.
Detailed projections of the current and future opportunity within the oligonucleotide synthesis industry across different therapeutic area, such as cardiovascular disorders, genetic disorders, liver disorders, rare diseases, and other disorders.
Detailed projections of the current and future opportunity within the field of oligonucleotide synthesis across different end-users, such as pharmaceutical / biopharmaceutical companies, academic and research institutes, and hospitals.
Detailed projections of the current and future opportunity within the field of oligonucleotide synthesis across different company size, such as small, mid-sized, and large and very large.
Detailed projections of the current and future opportunity within the oligonucleotide synthesis market across key geographical regions, such as North America, Europe, Asia-Pacific and Rest of the World.
Key Benefits of Buying this Report
The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
The report provides stakeholders with a pulse on the Oligonucleotide Synthesis Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
Leading Market Companies
Agilent Technologies
Ajinomoto Bio-Pharma Services
CordenPharma
Creative Biolabs
Ella Biotech
Eurofins Genomics
Future synthesis
Integrated DNA Technologies
Kaneka Eurogentec
LGC Biosearch Technologies
Merck
Microsynth
Nitto Avecia
Ribo Biotechnology
STA Pharmaceutical / Wuxi STA
Sumitomo Chemical
Thermo Fisher Scientific
TriLink Biotechnologies

ページTOPに戻る

Table of Contents

1. PREFACE
1.1. Oligonucleotide Synthesis Market Overview
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations

2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Future Estimates

3.2.2. Currency Coverage and Foreign Exchange Rate
3.2.2.1. Major Currencies Affecting the Market
3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
3.2.2.4. Strategies for Mitigating Foreign Exchange Risk

3.2.3. Trade Policies
3.2.3.1. Impact of Trade Barriers on the Market
3.2.3.2. Strategies for Mitigating The Risks Associated with Trade Barriers

3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY
4.1. Chapter Overview

5. INTRODUCTION
5.1. Chapter Overview
5.2. Oligonucleotide Structure
5.3. Types of Oligonucleotides
5.3.1. Antisense Oligonucleotides
5.3.2. Aptamers
5.3.3. miRNA
5.3.4. shRNA
5.3.5. siRNA
5.3.6. Other Oligonucleotides

5.4. Manufacturing of Oligonucleotides
5.4.1. Synthesis of Oligonucleotides
5.4.1.1. Process Development / Validation
5.4.1.2. Analytical Testing
5.4.1.3. Quality Control and Quality Assurance

5.4.2. Modification of Oligonucleotides
5.4.2.1. Backbone Modification
5.4.2.2. Sugar Ring Modification

5.4.3. Purification of Oligonucleotides
5.4.3.1. Cartridge Purification
5.4.3.2. Desalting
5.4.3.3. High Performance Liquid Chromatography
5.4.3.4. Polyacrylamide Gel Electrophoresis

5.4.4 Formulation of Oligonucleotides

5.5. Outsourcing Oligonucleotide Manufacturing
5.5.1. Need for Outsourcing
5.5.2. Advantages of Outsourcing Manufacturing Operations

5.6. Future Perspectives

6. MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Oligonucleotide Synthesis Providers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Company Size and Location of Headquarters
6.2.5. Analysis by Location of Oligonucleotide Synthesis Facilities
6.2.6. Analysis by Scale of Operation
6.2.7. Analysis by Type of Oligonucleotide Synthesized
6.2.8. Analysis by Type of Oligonucleotide Product Synthesized
6.2.9. Analysis by Application Area
6.2.10. Analysis by Type of Additional Service Offered

7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions and Key Parameters
7.3. Methodology
7.4. Oligonucleotide Synthesis Providers: Company Competitiveness Analysis
7.4.1. Oligonucleotide Synthesis Providers Based in North America
7.4.2. Oligonucleotide Synthesis Providers Based in Europe
7.4.3. Oligonucleotide Synthesis Providers Based in Asia- Pacific and Rest of the World

8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Detailed Company Profiles of Leading Service Providers
8.2.1. Agilent Technologies
8.2.1.1. Company Overview
8.2.1.2. Financial Information
8.2.1.3. Service Portfolio
8.2.1.4. Recent Developments and Future Outlook

8.2.2. Ajinomoto Bio-Pharma Services
8.2.2.1. Company Overview
8.2.2.2. Financial Information
8.2.2.3. Service Portfolio
8.2.2.4. Recent Developments and Future Outlook

8.2.3. CordenPharma
8.2.3.1. Company Overview
8.2.3.2. Service Portfolio
8.2.3.3. Recent Developments and Future Outlook

8.2.4. Integrated DNA Technologies
8.2.4.1. Company Overview
8.2.4.2. Service Portfolio
8.2.4.3. Recent Developments and Future Outlook

8.2.5. Kaneka Eurogentec
8.2.5.1. Company Overview
8.2.5.2. Financial Information
8.2.5.3. Service Portfolio
8.2.5.4. Recent Developments and Future Outlook

8.2.6. LGC Biosearch Technologies
8.2.6.1. Company Overview
8.2.6.2. Financial Information
8.2.6.3. Service Portfolio
8.2.6.4. Recent Developments and Future Outlook

8.2.7. Microsynth
8.2.7.1. Company Overview
8.2.7.2. Service Portfolio
8.2.7.3. Recent Developments and Future Outlook

8.2.8. Merck
8.2.8.1. Company Overview
8.2.8.2. Financial Information
8.2.8.3. Service Portfolio
8.2.8.4. Recent Developments and Future Outlook

8.2.9. Nitto Avecia
8.2.9.1. Company Overview
8.2.9.2. Financial Information
8.2.9.3. Service Portfolio
8.2.9.4. Recent Developments and Future Outlook

8.2.10. Thermo Fisher Scientific
8.2.10.1. Company Overview
8.2.10.2. Financial Information
8.2.10.3. Service Portfolio
8.2.10.4. Recent Developments and Future Outlook

8.2.11. TriLink BioTechnologies
8.2.11.1. Company Overview
8.2.11.2. Service Portfolio
8.2.11.3. Recent Developments and Future Outlook

8.3. Short Company Profiles of Leading Service Providers
8.3.1. Creative Biolabs
8.3.1.1. Company Overview
8.3.1.2. Service Portfolio

8.3.2. Ella Biotech
8.3.2.1. Company Overview
8.3.2.2. Service Portfolio

8.3.3. Eurofins Genomics
8.3.3.1. Company Overview
8.3.3.2. Service Portfolio

8.3.4. Future Synthesis
8.3.4.1. Company Overview
8.3.4.2. Service Portfolio

8.3.5. Ribo Biotechnology
8.3.5.1. Company Overview
8.3.5.2. Service Portfolio

8.3.6. STA Pharmaceutical
8.3.6.1. Company Overview
8.3.6.2. Service Portfolio

8.3.7. Sumitomo Chemical
8.3.7.1. Company Overview
8.3.7.2. Service Portfolio

9. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Oligonucleotide Synthesis: Make versus Buy Decision Making Framework
9.3.1. Scenario 1
9.3.2. Scenario 2
9.3.3. Scenario 3
9.3.4. Scenario 4

9.4. Concluding Remarks

10. CLINICAL TRIAL ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Oligonucleotide Therapeutics: Clinical Trial Analysis
10.3.1. Analysis by Trial Registration Year
10.3.2. Analysis by Trial Status
10.3.3. Analysis by Trial Registration Year and Trial Status
10.3.4. Analysis by Trial Phase
10.3.5. Analysis by Trial Registration Year and Trial Phase
10.3.6. Analysis of Enrolled Patient Population by Trial Registration Year
10.3.7. Analysis of Enrolled Patient Population by Trial Phase
10.3.8. Analysis by Type of Oligonucleotide
10.3.9. Analysis by Therapeutic Area
10.3.10. Analysis by Study Design
10.3.11. Analysis by Type of Sponsor
10.3.12. Most Active Players: Analysis by Number of Registered Trials
10.3.13. Analysis of Number of Registered Trials by Geography
10.3.14. Analysis of Number of Registered Trials by Trial Status and Geography
10.3.15. Analysis of Enrolled Patient Population by Geography
10.3.16. Analysis of Enrolled Patient Population by Trial Status and Geography

11. PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models
11.3. Oligonucleotide Synthesis: Partnerships and Collaborations
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3. Analysis by Year and Type of Partnership
11.3.4. Analysis by Type of Oligonucleotide
11.3.5. Analysis by Therapeutic Area
11.3.6. Analysis by Application Area
11.3.7. Most Active Players: Analysis by Number of Partnerships

11.3.8. Analysis by Geography
11.3.8.1. Intracontinental and Intercontinental Agreements
11.3.8.2. Local and International Agreements

12. RECENT EXPANSIONS
12.1. Chapter Overview
12.2. Type of Expansion
12.3. Oligonucleotide Synthesis: Recent Expansions
12.3.1. Analysis by Year of Expansion
12.3.2. Analysis by Type of Expansion
12.3.3. Analysis by Year and Type of Expansion
12.3.4. Analysis by Location of Expanded Facility
12.3.5. Analysis by Type of Expansion and Location of Expanded Facility
12.3.6. Analysis by Area of Expanded Facility
12.3.7. Analysis by Scale of Operation
12.3.8. Analysis by Amount Invested
12.3.9. Most Active Players: Analysis by Number of Expansions

13. BIG PHARMA INITIATIVES
13.1. Chapter Overview
13.2. Oligonucleotide Related Initiatives by Big Pharmaceutical Players
13.2.1. Analysis by Number of Initiatives
13.2.2. Analysis by Year of Initiative
13.2.3. Analysis by Type of Initiative
13.2.3.1. Analysis by Type of Partnership
13.2.3.2. Analysis by Type of Expansion
13.2.4. Analysis by Year and Type of Initiative
13.2.5. Analysis by Scale of Operation
13.2.6. Analysis by Type of Oligonucleotide
13.2.7. Analysis by Amount Invested

14. CAPACITY ANALYSIS
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Oligonucleotide Synthesis: Global Installed Capacity
14.3.1. Analysis by Company Size
14.3.2. Analysis by Geography
14.3.2.1. Analysis of Oligonucleotide Synthesis Capacity in North America
14.3.2.2. Analysis of Oligonucleotide Synthesis Capacity in Europe
14.3.2.3. Analysis of Oligonucleotide Synthesis Capacity in Asia-Pacific and Rest of the World

14.3.3. Concluding Remarks

15. DEMAND ANALYSIS
15.1 Chapter Overview
15.2. Assumptions and Methodology
15.3. Overall Demand for Oligonucleotides
15.4. Global Clinical Demand for Oligonucleotides
15.4.1. Analysis by Type of Oligonucleotide
15.4.2. Analysis by Therapeutic Area
15.4.3. Analysis by Geography

15.5. Global Commercial Demand for Oligonucleotides
15.5.1. Analysis by Type of Oligonucleotide
15.5.2. Analysis by Therapeutic Area
15.5.3. Analysis by Geography

16. MARKET IMPACT ANALYSIS
16.1. Chapter Overview
16.2. Market Drivers
16.3. Market Restraints
16.4. Market Opportunities
16.5. Market Challenges
16.6. Conclusion

17. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Global Oligonucleotide Synthesis Market, Historical Trends (2018-2023) and Future Estimates (2024-2035)
17.3.1. Scenario Analysis
17.3.1.1. Conservative Scenario
17.3.1.2. Optimistic Scenario

17.4. Key Market Segmentations

18. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION AREA
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Oligonucleotide Synthesis Market: Distribution by Application Area, 2018, 2024 and 2035
18.3.1. Research and Diagnostics: Historical Trends (2018-2023) and Future Estimates (2024-2035)
18.3.2. Therapeutics: Historical Trends (2018-2023) and Future Estimates (2024-2035)

18.4. Data Triangulation and Validation

19. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY TYPE OF PRODUCT SYNTHESIZED
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Oligonucleotide Synthesis Market: Distribution by Type of Product Synthesized, 2018, 2024 and 2035
19.3.1. Active Pharmaceutical Ingredients: Historical Trends (2018-2023) and Future Estimates (2024-2035)
19.3.2. Finished Dosage Forms: Historical Trends (2018-2023) and Future Estimates (2024-2035)

19.4. Data Triangulation and Validation

20. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY TYPE OF OLIGONUCLEOTIDE SYNTHESIZED
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Oligonucleotide Synthesis Market: Distribution by Type of Oligonucleotide Synthesized, 2018, 2024 and 2035
20.3.1. Antisense Oligonucleotides: Historical Trends (2018-2023) and Future Estimates (2024-2035)
20.3.2. DNA Oligonucleotides: Historical Trends (2018-2023) and Future Estimates (2024-2035)
20.3.3. siRNA Oligonucleotides: Historical Trends (2018-2023) and Future Estimates (2024-2035)
20.3.4. Other Oligonucleotides: Historical Trends (2018-2023) and Future Estimates (2024-2035)

20.4. Data Triangulation and Validation

21. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY SCALE OF OPERATION
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Oligonucleotide Synthesis Market: Distribution by Scale of Operation, 2018, 2024 and 2035
21.3.1. Clinical Scale of Operation: Historical Trends (2018-2023) and Future Estimates (2024-2035)
21.3.2. Commercial Scale of Operation: Historical Trends (2018-2023) and Future Estimates (2024-2035)

21.4. Data Triangulation and Validation

22. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY THERAPEUTIC AREA
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Oligonucleotide Synthesis Market: Distribution Therapeutic Area, 2018, 2024 and 2035
22.3.1. Cardiovascular Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
22.3.2. Genetic Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
22.3.3. Liver Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
22.3.4. Rare Diseases: Historical Trends (2018-2023) and Future Estimates (2024-2035)
22.3.5. Other Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)

22.4. Data Triangulation and Validation

23. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END-USERS
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Oligonucleotide Synthesis Market: Distribution by End-users, 2018, 2024 and 2035
23.3.1. Pharmaceutical / Biopharmaceutical Companies: Historical Trends (2018-2023) and Future Estimates (2024-2035)
23.3.2. Academic and Research Institutes: Historical Trends (2018-2023) and Future Estimates (2024-2035)
23.3.3. Hospitals: Historical Trends (2018-2023) and Future Estimates (2024-2035)

23.4. Data Triangulation and Validation

24. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COMPANY SIZE
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Oligonucleotide Synthesis Market: Distribution by Company Size, 2018, 2024 and 2035
24.3.1. Small Companies: Historical Trends (2018-2023) and Future Estimates (2024-2035)
24.3.2. Mid-sized Companies: Historical Trends (2018-2023) and Future Estimates (2024-2035)
24.3.3. Large and Very Large Companies: Historical Trends (2018-2023) and Future Estimates (2024-2035)

24.4. Data Triangulation and Validation

25. OLIGONUCLEOTIDE SYNTHESIS MARKET: DISTRIBUTION BY KEY GEOGRAPHICAL REGIONS
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Oligonucleotide Synthesis Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
25.3.1. North America: Historical Trends (2018-2023) and Future Estimates (2024-2035)
25.3.1.1. US: Historical Trends (2018-2023) and Future Estimates (2024-2035)
25.3.1.2. Canada: Historical Trends (2018-2023) and Future Estimates (2024-2035)
25.3.2. Europe: Historical Trends (2018-2023) and Future Estimates (2024-2035)
25.3.2.1. Switzerland: Historical Trends (2018-2023) and Future Estimates (2024-2035)
25.3.2.2. Germany: Historical Trends (2018-2023) and Future Estimates (2024-2035)
25.3.2.3. Belgium: Historical Trends (2018-2023) and Future Estimates (2024-2035)
25.3.2.4. Rest of Europe: Historical Trends (2018-2023) and Future Estimates (2024-2035)

25.3.3. Asia-Pacific: Historical Trends (2018-2023) and Future Estimates (2024-2035)
25.3.3.1. China: Historical Trends (2018-2023) and Future Estimates (2024-2035)
25.3.3.2. South Korea: Historical Trends (2018-2023) and Future Estimates (2024-2035)
25.3.3.3. Japan: Historical Trends (2018-2023) and Future Estimates (2024-2035)
25.3.3.4. India: Historical Trends (2018-2023) and Future Estimates (2024-2035)
25.3.3.5. Rest of Asia-Pacific: Historical Trends (2018-2023) and Future Estimates (2024-2035)
25.3.4. Rest of the World: Historical Trends (2018-2023) and Future Estimates (2024-2035)

25.4. Data Triangulation and Validation

26. EXECUTIVE INSIGHTS
26.1. Chapter Overview
26.2. BianoGMP
26.2.1. Company Snapshot
26.2.2. Interview Transcript

26.3. Hanugen Therapeutics
26.3.1. Company Snapshot
26.3.2. Interview Transcript

26.4. IBA Life Sciences
26.4.1. Company Snapshot
26.4.2 Interview Transcript

26.5. Axolabs
26.5.1. Company Snapshot
26.5.2. Interview Transcript

26.6. SBS Genetech
26.6.1. Company Snapshot
26.6.2. Interview Transcript

26.7. Aptagen
26.7.1. Company Snapshot
26.7.2. Interview Transcript

26.8. Invitek Diagnostics
26.8.1. Company Snapshot
26.8.2. Interview Transcript

27. CONCLUDING REMARKS
27.1. Chapter Overview

28. APPENDIX I: TABULATED DATA

29. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION

ページTOPに戻る

List of Tables/Graphs

Figure 2.1 Research Methodology: Research Assumptions
Figure 2.2 Research Methodology: Project Methodology
Figure 2.3 Research Methodology: Forecast Methodology
Figure 2.4 Research Methodology: Robust Quality Control
Figure 2.5 Research Methodology: Key Market Segmentations
Figure 4.1. Executive Summary: Overall Market Landscape (I/II)
Figure 4.2. Executive Summary: Overall Market Landscape (II/II)
Figure 4.3. Executive Summary: Clinical Trial Analysis
Figure 4.4. Executive Summary: Partnerships and Collaborations
Figure 4.5. Executive Summary: Recent Expansions
Figure 4.6. Executive Summary: Big Pharma Initiatives
Figure 4.7. Executive Summary: Capacity Analysis
Figure 4.8. Executive Summary: Demand Analysis
Figure 4.9. Executive Summary: Market Sizing and Opportunity Analysis
Figure 5.1. Classification of Oligonucleotides
Figure 5.2. Steps Involved in the Oligonucleotide Manufacturing
Figure 5.3. Types of Modifications of Oligonucleotides
Figure 5.4. Types of Purification Methods Used for Oligonucleotides
Figure 5.5. Commonly Outsourced Oligonucleotide Manufacturing Services
Figure 6.1. Oligonucleotide SynthesisProviders: Distribution by Year of Establishment
Figure 6.2. Oligonucleotide SynthesisProviders: Distribution by Company Size
Figure 6.3. Oligonucleotide SynthesisProviders: Distribution by Location of Headquarters
Figure 6.4. Oligonucleotide SynthesisProviders: Distribution by Company Size and Location of Headquarters
Figure 6.5. Oligonucleotide SynthesisProviders: Distribution by Location of Oligonucleotide Synthesis Facilities
Figure 6.6. Oligonucleotide SynthesisProviders: Distribution by Scale of Operation
Figure 6.7. Oligonucleotide SynthesisProviders: Distribution by Type of Oligonucleotide Synthesized
Figure 6.8. Oligonucleotide SynthesisProviders: Distribution by Type of ProductSynthesized
Figure 6.9. Oligonucleotide SynthesisProviders: Distribution by Application Area
Figure 6.10. Oligonucleotide Synthesis Providers: Distribution by Type of Additional Services Offered
Figure 7.1. Company CompetitivenessAnalysis: Oligonucleotide Synthesis Providers based in North America
Figure 7.2. Company CompetitivenessAnalysis: Oligonucleotide Synthesis Providers based in Europe
Figure 7.3. Company CompetitivenessAnalysis: Oligonucleotide Synthesis Providers based in Asia-Pacific and Rest of the World
Figure 8.1. Agilent Technologies: AnnualRevenues, FY 2018-FY 2023 (USD Billion)
Figure 8.2. Ajinomoto Bio-PharmaServices: Annual Revenues, FY 2019-H1 FY 2023 (YEN Billion)
Figure 8.3. Kaneka: Annual Revenues, FY2019-Q1 FY 2023 (YEN Billion)
Figure 8.4. LGC Group: Annual Revenues,FY 2019-FY 2023 (GBP Million)
Figure 8.5. Merck: Annual Revenues, FY2019-9M FY 2023 (EUR Billion)
Figure 8.6. Nitto Avecia: AnnualRevenues, FY 2019-H1 FY 2023 (YEN Billion)
Figure 8.7. Thermo Fisher Scientific:Annual Revenues, FY 2019-9M FY 2023 (USD Billion)
Figure 9.1. Make versus Buy Decision Making Framework
Figure 9.2. Make versus Buy Decision Making: Possible Scenarios
Figure 10.1. Clinical Trial Analysis: Scopeand Methodology
Figure 10.2. Clinical Trial Analysis:Cumulative Year-wise Trend, Pre-2015-2023
Figure 10.3. Clinical Trial Analysis:Distribution by Trial Status
Figure 10.4. Clinical Trial Analysis:Distribution by Trial Registration Year and Trial Status, 2015-2023
Figure 10.5. Clinical Trial Analysis:Distribution by Trial Phase
Figure 10.6. Clinical Trial Analysis:Distribution by Trial Registration Year and Trial Phase, Pre-2007 - Post-2018
Figure 10.7. Clinical Trial Analysis:Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2015-2023
Figure 10.8. Clinical Trial Analysis:Distribution of Enrolled Patient Population by Trial Phase
Figure 10.9. Clinical Trial Analysis: Distribution by Type of Oligonucleotide
Figure 10.10. Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 10.11. Clinical Trial Analysis: Distribution by Study Design
Figure 10.12. Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 10.10. Most Active Players: Distribution by Number of Registered Trials
Figure 10.14. Clinical Trial Analysis: Distribution of Registered Trials by Geography
Figure 10.15. Clinical Trial Analysis: Distribution of Registered Trials by Trial Status and Geography
Figure 10.16. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Figure 10.17. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
Figure 11.1. Partnerships andCollaborations: Cumulative Year-wise Trend, 2014-2023
Figure 11.2. Partnerships andCollaborations: Distribution by Type of Partnership
Figure 11.3. Partnerships andCollaborations: Distribution by Year and Type of Partnership
Figure 11.4. Partnerships andCollaborations: Distribution by Type of Oligonucleotide
Figure 11.5. Partnerships andCollaborations: Distribution by Therapeutic Area
Figure 11.6. Partnerships andCollaborations: Distribution by Application Area
Figure 11.7. Most Active Players:Distribution by Number of Partnerships
Figure 11.8. Partnerships andCollaborations: Intracontinental and Intercontinental Agreements
Figure 11.8. Partnerships andCollaborations: Local and International Agreements
Figure 12.1. Recent Expansions:Cumulative Year-wise Trend, 2015-2023
Figure 12.2. Recent Expansions:Distribution by Type of Expansion
Figure 12.3. Recent Expansions:Distribution by Year and Type of Expansion
Figure 12.4. Recent Expansions:Distribution by Location of Expanded Facility
Figure 12.5. Recent Expansions:Distribution by Type of Expansion and Location of Expanded Facility
Figure 12.6. Recent Expansions:Distribution by Area of Expanded Facility (sq. ft.)
Figure 12.7. Recent Expansions:Distribution by Scale of Operation
Figure 12.8. Recent Expansions:Distribution by Amount Invested (USD Million)
Figure 12.9. Most Active Players:Distribution by Number of Recent Expansions
Figure 13.1. Big Pharma Initiatives:Distribution by Number of Initiatives
Figure 13.2. Big Pharma Initiatives:Distribution by Year of Initiative, Pre-2020-2023
Figure 13.3. Big Pharma Initiatives:Distribution by Type of Initiative
Figure 13.4. Big Pharma Initiatives:Distribution by Type of Partnership
Figure 13.5. Big Pharma Initiatives:Distribution by Type of Expansion
Figure 13.6. Big Pharma Initiatives:Distribution by Year and Type of Initiative
Figure 13.7. Big Pharma Initiatives:Distribution by Scale of Operation
Figure 13.8. Big Pharma Initiatives:Distribution by Type of Oligonucleotide
Figure 13.9. Big Pharma Initiatives:Distribution by Amount Invested (USD Million)
Figure 14.1. Capacity Analysis: Distribution by Company Size
Figure 14.2. Capacity Analysis: Distribution by Location of Synthesis Facility
Figure 14.3. Distribution ofOligonucleotide Synthesis Capacity in North America
Figure 14.4. Distribution ofOligonucleotide Synthesis Capacity in Europe
Figure 14.5. Distribution ofOligonucleotide Synthesis Capacity in Asia-Pacific and Rest of the World
Figure 15.1. Overall Demand for Oligonucleotides, 2024-2035 (in kilograms)
Figure 15.2. Global Clinical Demand for Oligonucleotides, 2024-2035 (in kilograms)
Figure 15.3. Global Clinical Demand for Oligonucleotides, 2024-2035: Distribution by Type of Oligonucleotide (in kilograms)
Figure 15.4. Global Clinical Demand for Oligonucleotides, 2024-2035: Distribution by Therapeutic Area (in kilograms)
Figure 15.5. Global Clinical Demand for Oligonucleotides, 2024-2035: Distribution by Geography (in kilograms)
Figure 15.6. Global Commercial Demand for Oligonucleotides, 2024-2035 (in kilograms)
Figure 15.7. Global Commercial Demand for Oligonucleotides, 2024-2035: Distribution by Type of Oligonucleotide (in kilograms)
Figure 15.8. Global Commercial Demand for Oligonucleotides, 2024-2035: Distribution by Therapeutic Area (in kilograms)
Figure 15.9. Global Commercial Demand for Oligonucleotides, 2024-2035: Distribution by Geography (in kilograms)
Figure 16.1. Oligonucleotide Synthesis: Market Drivers
Figure 16.2. Oligonucleotide Synthesis: Market Restraints
Figure 16.3. Oligonucleotide Synthesis: Market Opportunities
Figure 16.4. Oligonucleotide Synthesis: Market Challenges
Figure 17.1. Global Oligonucleotide Synthesis Market, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 17.2. Global Oligonucleotide Synthesis Market, 2024-2035: Conservative Scenario (USD Billion)
Figure 17.3. Oligonucleotide Synthesis Market, 2024-2035: Optimistic Scenario (USD Billion)
Figure 18.1. Oligonucleotide Synthesis Market: Distribution by Application Area, 2018, 2024 and 2035 (USD Billion)
Figure 18.2. Oligonucleotide Synthesis Market for Research and Diagnostics, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 18.3. Oligonucleotide Synthesis Market for Therapeutics, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 19.1. Oligonucleotide Synthesis Market: Distribution by Type of Product Synthesized, 2018, 2024 and 2035 (USD Billion)
Figure 19.2. Oligonucleotide Synthesis Market for Active Pharmaceutical Ingredients, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 19.3. Oligonucleotide Synthesis Market for Finished Dosage Forms, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 20.1. Oligonucleotide Synthesis Market: Distribution by Type of Oligonucleotide Synthesized, 2018, 2024 and 2035 (USD Billion)
Figure 20.2. Oligonucleotide Synthesis Market for Antisense Oligonucleotides, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 20.3. Oligonucleotide Synthesis Market for DNA Oligonucleotides, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 20.4. Oligonucleotide Synthesis Market for siRNA Oligonucleotides, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 20.5. Oligonucleotide Synthesis Market for Other Oligonucleotides, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 21.1. Oligonucleotide Synthesis Market: Distribution by Scale of Operation, 2018, 2024 and 2035 (USD Billion)
Figure 21.1. Oligonucleotide Synthesis Market for Commercial Operations, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 21.2 Oligonucleotide Synthesis for Clinical Operations, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 22.1. Oligonucleotide Synthesis Market: Distribution by Therapeutic Area, 2018, 2024 and 2035 (USD Billion)
Figure 22.2. Oligonucleotide Synthesis Market for Rare Diseases, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 22.3. Oligonucleotide Synthesis Market for Liver Disorders, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 22.4. Oligonucleotide Synthesis Market for Genetic Disorders, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 22.5. Oligonucleotide Synthesis Market for Cardiovascular Disorders, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 22.6. Oligonucleotide Synthesis Market for Other Disorders, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 23.1. Oligonucleotide Synthesis Market: Distribution by End-users, 2018, 2024 and 2035 (USD Billion)
Figure 23.2. Oligonucleotide Synthesis Market for Pharmaceutical / Biopharmaceutical Companies, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 23.3. Oligonucleotide Synthesis Market for Academic and Research Institutes, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 23.4. Oligonucleotide Synthesis Market for Hospitals, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 24.1. Oligonucleotide Synthesis Market: Distribution by Company Size, 2018, 2024 and 2035 (USD Billion)
Figure 24.2. Oligonucleotide Synthesis Market for Large and Very Large Companies, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 24.3. Oligonucleotide Synthesis Market for Mid-sized Companies, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 24.4. Oligonucleotide Synthesis Market for Small Companies, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 25.1. Oligonucleotide Synthesis Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035 (USD Billion)
Figure 25.2. Oligonucleotide Synthesis Market in North America, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 25.3 Oligonucleotide Synthesis Market in the US, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 25.4 Oligonucleotide Synthesis Market in Canada, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 25.5. Oligonucleotide Synthesis Market in Europe, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 25.6 Oligonucleotide Synthesis Market in Switzerland, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 25.7 Oligonucleotide Synthesis Market in Germany, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 25.8 Oligonucleotide Synthesis Market in Belgium, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 25.9. Oligonucleotide Synthesis Market in Rest of Europe, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 25.10 Oligonucleotide Synthesis Market in Asia-Pacific, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 25.11 Oligonucleotide Synthesis Market in China, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion) (USD Billion)
Figure 25.12 Oligonucleotide Synthesis Market in South Korea, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion) (USD Billion)
Figure 25.13 Oligonucleotide Synthesis Market in Japan, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion) (USD Billion)
Figure 25.14 Oligonucleotide Synthesis Market in India, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion) (USD Billion)
Figure 25.15 Oligonucleotide SynthesisMarket in Rest of Asia-Pacific, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 25.16 Oligonucleotide SynthesisMarket in Rest of the World, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 27.1. Concluding Remarks: Oligonucleotide Synthesis: Overall Market Landscape
Figure 27.2. Concluding Remarks: Oligonucleotide Synthesis: Clinical Trial Analysis
Figure 27.3. Concluding Remarks: Oligonucleotide Synthesis: Partnerships and Collaborations
Figure 27.4. Concluding Remarks: Oligonucleotide Synthesis: Recent Expansions
Figure 27.5. Concluding Remarks: Oligonucleotide Synthesis: Big Pharma Initiatives
Figure 27.6. Concluding Remarks: Oligonucleotide Synthesis: Capacity Analysis
Figure 27.7. Concluding Remarks: Oligonucleotide Synthesis: Demand Analysis
Figure 27.8. Concluding Remarks:Oligonucleotide Synthesis: Market Sizing and Opportunity Analysis (I/II)
Figure 27.9. Concluding Remarks:Oligonucleotide Synthesis: Market Sizing and Opportunity Analysis (II/II)